Bioheart and PharmaCell Open GMP Lab Facility in Europe
Complete the form below to unlock access to ALL audio articles.
Bioheart Inc. and PharmaCell have announced the grand opening of a GMP lab facility in Maastricht, The Netherlands. The lab facility is in compliance with EU Good Manufacturing Practices (EU-GMP).
This lab is an advanced research facility that also has GMP cell production capabilities to support research related to Bioheart's adult muscle stem cell technology.
Bioheart has developed MyoCell™, a cell therapy that involves extracting and culturing cells from a patient's own thigh muscle.
These cells are inserted back into the patient's damaged heart region via the MyoCath®, a minimally-invasive injection-catheter system.
"We are excited about the opening of this GMP facility that will support our research," said Howard J. Leonhardt, Chairman and CEO of Bioheart.
"We chose the Maastricht region due to its highly educated workforce and its ideal location with close proximity to top research institutes such as the University of Maastricht," he added.
